Betul Uzunoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Betul Uzunoglu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Osman Melih Topcuoglu
Department of Radiology, Yeditepe University Hospitals, Kosuyolu, Istanbul, 34718, Turkey.
4 shared publications - Ayşegul Gormez
Department of Radiology, Yeditepe University Hospitals, Kosuyolu, Istanbul, 34718, Turkey
2 shared publications - Behiç Çelik
Yeditepe University
1 shared publication - Budak Akman
Department of Orthopaedics and Traumatology, Ataşehir Florence Nightingale Hospital, İstanbul, Turkey
1 shared publication - Cüneyt Türkmen
Department of Nuclear Medicine, Yeditepe University Hospitals, Kosuyolu, Istanbul, 34752, Turkey
1 shared publication Ekin Bora Basaran
Yeditepe University Hospitals, Department of Radiology, Kosuyolu 34718, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 3 (6)
Art of imaging: Breath in nature
- 18 September 2026
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 3 (6)
Open AccessArt of imaging: Breath in nature
- Open Access
- 22 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
Tumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?
Purpose: To assess the dose-response and dose-survival outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) using Therasphere microspheres in patients with colorectal cancer liver metastases (CRCLM). Material and methods: Between May 2014 and December 2024, patients with chemorefractory CRCLM who underwent Y90 TARE using glass microspheres were retrospectively included. Patients were divided into two groups according to tumour absorbed dose (TAD): TAD<189 Gy (group 1) and TAD ≥189 Gy (group 2). The primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate (ORR). Results: A total of seventy-eight patients with a mean age of 69.9±11.2 years (range 41 to 91 years) were included. The median tumor dose and the median OS were 171.5 Gy (IQR; 147-200 Gy) and 8.9 months ( IQR; 5-14 months), respectively. The median TAD for groups 1 (n=46) and 2 (n=32) was 150 Gy (IQR; 122-166 Gy) and 202 Gy (IQR; 195-232 Gy), respectively. The median OS and hPFS for group 1 versus group 2 were 9.4 months (IQR; 6.7–17.7 months) and 5.2 months (IQR; 4-6.7 months) versus 7.1 months (IQR; 5–10.7 months) and 5.5 months (IQR; 4.2-6.7 months), respectively and were not significantly different (p = .107 and p = .663, respectively). The ORR did not differ significantly between the two groups (p = .943). Conclusion: In a real-world population of heavily pretreated patients with CRCLM, escalation of TAD beyond 189 Gy did not translate into improved survival, highlighting the dominant impact of advanced disease burden and extrahepatic progression.
- 22 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
Open AccessTumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?
Purpose: To assess the dose-response and dose-survival outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) using Therasphere microspheres in patients with colorectal cancer liver metastases (CRCLM). Material and methods: Between May 2014 and December 2024, patients with chemorefractory CRCLM who underwent Y90 TARE using glass microspheres were retrospectively included. Patients were divided into two groups according to tumour absorbed dose (TAD): TAD<189 Gy (group 1) and TAD ≥189 Gy (group 2). The primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate (ORR). Results: A total of seventy-eight patients with a mean age of 69.9±11.2 years (range 41 to 91 years) were included. The median tumor dose and the median OS were 171.5 Gy (IQR; 147-200 Gy) and 8.9 months ( IQR; 5-14 months), respectively. The median TAD for groups 1 (n=46) and 2 (n=32) was 150 Gy (IQR; 122-166 Gy) and 202 Gy (IQR; 195-232 Gy), respectively. The median OS and hPFS for group 1 versus group 2 were 9.4 months (IQR; 6.7–17.7 months) and 5.2 months (IQR; 4-6.7 months) versus 7.1 months (IQR; 5–10.7 months) and 5.5 months (IQR; 4.2-6.7 months), respectively and were not significantly different (p = .107 and p = .663, respectively). The ORR did not differ significantly between the two groups (p = .943). Conclusion: In a real-world population of heavily pretreated patients with CRCLM, escalation of TAD beyond 189 Gy did not translate into improved survival, highlighting the dominant impact of advanced disease burden and extrahepatic progression.
- Open Access
- 5 December 2025
- Published by Associacao Brasileira de Medicina e Cirurgia do Tornozelo e Pe (ABTPe) in Journal of the Foot & Ankle
- Vol. 19 (3) , 1-7
When rare conditions collide: plantar vein thrombosis in hereditary spherocytosis
Plantar heel pain is a common orthopedic complaint, but less frequent etiologies like plantar vein thrombosis (PVT) are often overlooked. We present the case of a 27-year-old female with a history of hereditary spherocytosis who developed left plantar foot pain shortly after starting combined oral contraceptives. Initially suspected to be plantar fasciitis, conservative treatment provided no relief. Imaging studies, including Doppler ultrasonography and MRI, revealed a thrombus in the medial plantar vein. The patient was successfully treated with a 30-day course of anticoagulation therapy using enoxaparin, followed by acetylsalicylic acid. Her symptoms resolved completely, and she remained asymptomatic at a one-year follow-up. This unique case highlights the importance of considering PVT in the differential diagnosis of atypical foot pain, particularly in patients with a history of thrombotic risk factors, to ensure early and effective treatment. Level evidence IV.
- 5 December 2025
- Published by Associacao Brasileira de Medicina e Cirurgia do Tornozelo e Pe (ABTPe) in Journal of the Foot & Ankle
- Vol. 19 (3) , 1-7
Open AccessWhen rare conditions collide: plantar vein thrombosis in hereditary spherocytosis
Plantar heel pain is a common orthopedic complaint, but less frequent etiologies like plantar vein thrombosis (PVT) are often overlooked. We present the case of a 27-year-old female with a history of hereditary spherocytosis who developed left plantar foot pain shortly after starting combined oral contraceptives. Initially suspected to be plantar fasciitis, conservative treatment provided no relief. Imaging studies, including Doppler ultrasonography and MRI, revealed a thrombus in the medial plantar vein. The patient was successfully treated with a 30-day course of anticoagulation therapy using enoxaparin, followed by acetylsalicylic acid. Her symptoms resolved completely, and she remained asymptomatic at a one-year follow-up. This unique case highlights the importance of considering PVT in the differential diagnosis of atypical foot pain, particularly in patients with a history of thrombotic risk factors, to ensure early and effective treatment. Level evidence IV.
- 22 October 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (11) , 1821-1822
Lessons in IR: Endovascular Repair of Brachiocephalic Vein Perforation and Hemothorax during Tunneled Dialysis Catheter Placement
- 22 October 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (11) , 1821-1822
Lessons in IR: Endovascular Repair of Brachiocephalic Vein Perforation and Hemothorax during Tunneled Dialysis Catheter Placement
- 11 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107833
Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases
- 11 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107833
Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases
- 22 November 2024
- Published by Elsevier in Clinical Imaging
- Vol. 117, 110366
A real-world comparison of the diagnostic performances of six different TI-RADS guidelines, including ACR-/Kwak-/K-/EU-/ATA-/C-TIRADS
- 22 November 2024
- Published by Elsevier in Clinical Imaging
- Vol. 117, 110366
A real-world comparison of the diagnostic performances of six different TI-RADS guidelines, including ACR-/Kwak-/K-/EU-/ATA-/C-TIRADS